Sidley represented Alebund Pharmaceuticals (Alebund) in its option and license agreement with Chugai Pharmaceutical Co., Ltd. (Chugai) in relation to EOS789, an oral inhibitor of phosphate transporters under development for the treatment of hyperphosphatemia. Alebund plans to conduct an early-stage efficacy clinical trial to further evaluate EOS789. If Alebund exercises the option, Chugai will grant Alebund an exclusive license to develop, manufacture, and commercialize EOS789 for all indications worldwide, including Japan.
Founded in Shanghai in early 2018, Alebund is a clinical-stage biopharmaceutical company which is dedicated to the discovery and development of novel therapies for patients with kidney diseases and related chronic conditions.
The Sidley team was led by partners Ruchun Ji (Shanghai and Palo Alto), Thomas Duley (San Francisco), and Samuel Tiu (Los Angeles), with the support of associate Longbo Wang (Shanghai).
Sidley provides multidisciplinary services for life sciences clients. We advise clients across the full spectrum of their business lifecycles, ranging from formation, corporate governance, and compliance operations for start-ups, to collaboration, licensing, commercialization, and filing in the business development phase, including initial public offerings, equity financings, and bond/note issuances, as well as domestic and cross-border mergers and acquisitions, asset restructuring, equity incentive plans, and privatizations.